We use cookies for a better user experience. Read our Privacy Policy

I Agree

Mice Model Technologies Market

Mice Model Technologies Market (Technology: CRISPR Knockout; CRISPR Knockin; Random Insertions; Large, Targeted Insertions; ES Cell Modification; and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Mice Model Technologies Market Outlook 2031

  • The global mice model technologies market was valued at US$ 1.6 Bn in 2021
  • The global market is projected to grow at a CAGR of 7.4% from 2022 to 2031
  • The global mice model technologies market is anticipated to reach US$ 3.2 Bn by 2031

Analysts’ Viewpoint on Mice Model Technologies Market Scenario

High incidence of genetic disorders worldwide has led to significant R&D investment in genetic testing and rise in adoption of the CRISPR technology in the healthcare industry. CRISPR/Cas9 gene editing, an emerging technology, is extensively used to make mutations in all kinds of organisms. There is also an eminent need for accurate and speedy treatment with the rise in cases of various contagious diseases. Such scenarios have led to an increase in focus on NOD SCID gamma mouse (NSG mice), the model of choice for humanized mice, cell biology, cancer xenograft modeling, and infectious disease research. The global mice model technologies market is expected to grow at a substantial pace, owing to R&D in vaccines and drugs to curb the spread of COVID-19. Furthermore, increase in demand for personalized medicines and rise in prevalence of chronic diseases are also expected to drive the global mice model technologies market size.

Mice Model Technologies Market

Global Mice Model Technologies Market Introduction

Animal model is a non-human species, which can mimic characteristics of a biological process or a disease found in humans. Animal models are used in biomedical research. Genetic engineering is used to develop different types of mice models to target specific human diseases. Mice model technologies are often adopted in biomedical research, as mice share mammalian features with humans and suffer from many similar diseases.

Request a sample to get extensive insights into the Mice Model Technologies Market

Surge in Investment in Biomedical Research to Drive Demand for Mice Model Technologies

Investment in biomedical research is considered one of the most important indicators of any country’s research landscape. In the last decade, biomedical research expenditure has increased manifold across the globe, with developed countries such as the U.S. and the U.K. dominating the landscape. Majority of these investments are made for R&D of animal models.

The National Institutes of Health (NIH), the largest advocate of biomedical research in the world, had a budget of around US$ 31 Bn in 2019, followed by the Bill & Melinda Gates Foundation (BMGF) and the Wellcome Trust (each with approximately US$ 1.08 Bn; 3.1%). Overall, around 89.6% (approximately US$ 32 Bn) of all the grants awarded for biomedical research were allocated to recipient organizations in the U.S. More than 60% of NIH extramural funding involves animal-related research; most of this is allocated to mice-related studies. Thus, increase in biomedical research funding is expected to drive the global mice model technologies market during the forecast period.

Rise in Adoption of Advanced Genomic Techniques

Various techniques and methodologies have been developed in the past few years to create genetically modified mice models of human diseases. Homologous recombination in embryonic stem cells is the conventional way of gene targeting. The advent of new molecular genome-altering technologies such as CRISPR/Cas9 allows for genetic mutations to be introduced into the germ line of a mouse faster and cheaper than previous methods.

Development of mice models is significantly easier than before with the use of CRISPR-based techniques. These techniques can be employed to effectively and quickly (within two to three months) produce frequently used mice models (simple knockout mouse, CRISPR Knockin mouse, point mutation knock-in mouse, cKOs, and reporter/Cre knock-ins). One or two guide RNAs and Cas9 protein can be injected to generate knockout mice. Development of large knock-ins (approximately 5 to 10 kb long) is generally achieved using plasmid DNAs as donors. CRISPR editing or ESC-mediated gene targeting can be used to create humanized knock-in (KI) mice models; each technique has its advantages for model development.

Cyagen TurboKnockout gene targeting service combines benefits of each approach to enable sophisticated gene modeling in C57BL/6 or BALB/c mouse models on an accelerated timeframe, including LFKIs up to 300 kb. In as little as six months, TurboKnockout can provide research-ready mouse models for humanization.

Request a custom report on Mice Model Technologies Market

High Efficiency of CRISPR Gene Editing Technology Boosting CRISPR Knockout Segment

In terms of technology, the global mice model technologies market has been segregated into CRISPR Knockout; CRISPR Knockin; random insertions, large, targeted insertions; ES cell modification (homologous recombination); and others. The CRISPR Knockout segment held dominant share of the market in 2021. It is expected to maintain its dominance during the forecast period. Growth of the segment can be ascribed to high efficiency of CRISPR gene editing technology and increase in adoption of CRISPR technology for the development of CRISPR Knockout mice.

Increase in Adoption of CRISPR Technology in Biotechnology Companies

Based on end-user, the global mice model technologies market has been classified into pharmaceutical companies, biotechnology companies, academic and research facilities, and contract research and manufacturing organizations.

The biotechnology companies segment is projected to account for dominant share of the global mice model technologies market during the forecast period. Increase in adoption of CRISPR technology in biotechnology companies and research laboratories is driving the segment. For instance, in October 2016, Caribou Biosciences granted The Jackson Laboratory non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically-engineered mice for research purposes.

The academic and research facilities segment is expected to grow at a higher rate during the forecast period. Growth of the segment can be ascribed to the rise in funding for academic and research facilities for R&D in mice model technologies.

Regional Outlook of Global Mice Model Technologies Market

North America dominated the global mice model technologies market, with more than 40% share in 2021. According to the mice model technologies market research study, rise in research and development activities in CRISPR to provide modified products for prevention and treatment of various chronic and rare diseases, such as sickle cell anemia and Alzheimer’s diseases, is expected to fuel the market in North America in the near future.

Asia Pacific is also poised to witness significant growth during the forecast period, owing to the increase in adoption of mice models for R&D in COVID-19 prevention and treatment.

Analysis of Key Players in Global Mice Model Technologies Market

The global mice model technologies market is fragmented, with the presence of international as well as local players. Manufacturers in the market are striving to build a strong network of vendors to enable seamless distribution of products. Players are also focused on adopting strategies such as collaboration, partnership, joint venture, and merger and acquisition to enhance their mice model technologies market share.

Key players operating in the global mice model technologies market include Biocytogen, Charles River Laboratories, Cyagen Biosciences, Gempharmatech, GenOway, Ingenious Targeting Laboratory, Merck KGaA, Ozgene Pty Ltd., Taconic Biosciences, Inc., PolyGene AG, The Jackson Laboratory, Yale School of Medicine, University of North Carolina, University of Nebraska Medical Center, Monash University, UMass Chan Medical School, University of Bonn, Columbia University, and The University of Arizona.

Key Developments in Global Mice Model Technologies Market

  • In July 2022, GemPharmatech announced that it had entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America
  • In March 2022, Charles River Laboratories signed an agreement to breed, distribute, market, and sell Hera BioLabs' SRG rat to the global preclinical research community. Unlike other immunodeficient rodent strains such as the nude rat, the SRG (Sprague Dawley, Rag2, Il2rg-"SRG") is a severely immunodeficient model created through knockout mutations in the Rag2 and Il2r gamma genes that results in mature B, T, and NK cell deficiencies. This severe immunodeficiency, combined with a larger organism size, makes the SRG rat an ideal alternative research model to mice in certain preclinical applications.
  • In May 2021, the La Jolla Institute for Immunology (LJI) entered into a partnership agreement with Synbal, Inc. to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI is expected to be led by Professor Shresta. By combining Synbal’s proprietary gene-editing platform called Active Genetics with Shresta’s expertise in the characterization of immune responses to emerging and re-emerging viral pathogens, the team plans to develop several humanized mouse models to study Covid-19.
  • In May 2020, Oragenics, Inc. announced that it had entered into an agreement with Aragen Bioscience to advance TerraCov2, the company’s SARS CoV-2 vaccine candidate, through Noachis Terra, its wholly-owned subsidiary. As per the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of TerraCoV2, which could provide specific immunity from the novel coronavirus, the root cause of Covid-19.
  • In March 2019, Charles River Laboratories inked a licensing deal with Crown Bioscience, a drug discovery and development services provider, for expanded access to the Zucker Diabetic Sprague-Dawley (ZDSD) rat model. As per the deal, Charles River gets an exclusive license to breed and distribute the ZDSD model. In return, Crown Bio is guaranteed a premium-quality and prioritized supply of ZDSD models to support its service platforms.
  • In December 2018, Merck announced a strategic alliance in the CRISPR/Cas9 rodent model market with genOway, a France-based biotechnology company

Each of these players has been profiled in the mice model technologies market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Mice Model Technologies Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.6 Bn

Market Forecast Value in 2031

US$ 3.2 Bn

Growth Rate

(CAGR)

7.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Example: Electronic (PDF) + Excel

Market Segmentation

  • Technology
    • CRISPR Knockout
    • CRISPR Knockin
    • Random Insertions
    • Large, Targeted Insertions
    • ES Cell Modification (Homologous Recombination)
    • Others
  • End-user
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Academic and Research Facilities
    • Contract Research and Manufacturing Organizations

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • BIOCYTOGEN
  • Charles River Laboratories
  • Cyagen Biosciences
  • Gempharmatech
  • genOway
  • ingenious targeting laboratory
  • Merck KGaA
  • Ozgene Pty Ltd.
  • Taconic Biosciences, Inc.
  • PolyGene AG
  • THE JACKSON LABORATORY
  • Yale School of Medicine
  • University of North Carolina
  • University of Nebraska Medical Center
  • Monash University
  • UMass Chan Medical School
  • University of Bonn
  • Columbia University
  • The University of Arizona

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global mice model technologies market in 2021?

The global mice model technologies market was valued at US$ 1.6 Bn in 2021

How big will be the global mice model technologies market in 2031?

The global mice model technologies market is projected to reach US$ 3.2 Bn by 2031

What was the CAGR of the global mice model technologies market from 2017–2021?

The global mice model technologies market grew at a CAGR of 6.7% from 2017 to 2021

What will be the CAGR of the global mice model technologies market during the forecast period (2022–2031)?

The global mice model technologies market is anticipated to grow at a CAGR of 7.4% from 2022 to 2031

Which are the prominent trends that affect the market growth?

Increase in R&D in gene technology due to the need for accurate and speedy treatment of various diseases and rise in adoption of advanced genomic techniques

What was the market share of the leading segment of the global mice model technologies market?

The CRISPR knockout segment accounted for more than 25% share of the global mice model technologies market in 2021

Which region will account for the major share of the global market during the forecast period?

North America is expected to account for major share of the global market during the forecast period

Who are the prominent players in the global mice model technologies market?

Biocytogen, Charles River Laboratories, Cyagen Biosciences, Gempharmatech, GenOway, Ingenious Targeting Laboratory, Merck KGaA, Ozgene Pty Ltd., Taconic Biosciences, Inc., PolyGene AG, The Jackson Laboratory, Yale School of Medicine, University of North Carolina, University of Nebraska Medical Center, Monash University, UMass Chan Medical School, University of Bonn, Columbia University, and The University of Arizona

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Technologies Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Mice Model Technologies Market Analysis and Forecasts, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Global Genetically Engineered Mouse Model Overview

    5.2. Regulatory Scenario by Region/globally

    5.3. Technological Advancements

    5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)

    5.5. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Mice Model Technologies Market Analysis and Forecasts, By Technology

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Technology, 2017–2031

        6.3.1. CRISPR Knockout

        6.3.2. CRISPR Knockin

        6.3.3. Random Insertions

        6.3.4. Large, Targeted Insertions

        6.3.5. ES Cell Modification (Homologous Recombination)

        6.3.6. Others

    6.4. Market Attractiveness By Technology

7. Global Mice Model Technologies Market Analysis and Forecasts, By End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By End-user, 2017–2031

        7.3.1. Pharmaceutical Companies

        7.3.2. Biotechnology Companies

        7.3.3. Academic and Research Facilities

        7.3.4. Contract Research and Manufacturing Organizations

    7.4. Market Attractiveness By End-user

8. Global Mice Model Technologies Market Analysis and Forecasts, By Region

    8.1. Key Findings

    8.2. Market Value Forecast By Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness By Country/Region

9. North America Mice Model Technologies Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast By Technology, 2017–2031

        9.2.1. CRISPR Knockout

        9.2.2. CRISPR Knockin

        9.2.3. Random Insertions

        9.2.4. Large, Targeted Insertions

        9.2.5. ES Cell Modification (Homologous Recombination)

        9.2.6. Others

    9.3. Market Value Forecast By End-user, 2017–2031

        9.3.1. Pharmaceutical Companies

        9.3.2. Biotechnology Companies

        9.3.3. Academic and Research Facilities

        9.3.4. Contract Research and Manufacturing Organizations

    9.4. Market Value Forecast By End-user by Technology, 2017–2031

        9.4.1. Pharmaceutical Companies

            9.4.1.1. CRISPR Knockout

            9.4.1.2. CRISPR Knockin

            9.4.1.3. Random Insertions

            9.4.1.4. Large, Targeted Insertions

            9.4.1.5. ES Cell Modification (Homologous Recombination)

            9.4.1.6. Others

        9.4.2. Biotechnology Companies

            9.4.2.1. CRISPR Knockout

            9.4.2.2. CRISPR Knockin

            9.4.2.3. Random Insertions

            9.4.2.4. Large, Targeted Insertions

            9.4.2.5. ES Cell Modification (Homologous Recombination)

            9.4.2.6. Others

        9.4.3. Academic and Research Facilities

            9.4.3.1. CRISPR Knockout

            9.4.3.2. CRISPR Knockin

            9.4.3.3. Random Insertions

            9.4.3.4. Large, Targeted Insertions

            9.4.3.5. ES Cell Modification (Homologous Recombination)

            9.4.3.6. Others

        9.4.4. Contract Research and Manufacturing Organizations

            9.4.4.1. CRISPR Knockout

            9.4.4.2. CRISPR Knockin

            9.4.4.3. Random Insertions

            9.4.4.4. Large, Targeted Insertions

            9.4.4.5. ES Cell Modification (Homologous Recombination)

            9.4.4.6. Others

    9.5. Market Value Forecast By Country, 2017–2031

        9.5.1. U.S.

        9.5.2. Canada

    9.6. Market Attractiveness Analysis

        9.6.1. By Technology

        9.6.2. By End-user

        9.6.3. By End-user by Technology

        9.6.4. By Country

10. Europe Mice Model Technologies Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast By Technology, 2017–2031

        10.2.1. CRISPR Knockout

        10.2.2. CRISPR Knockin

        10.2.3. Random Insertions

        10.2.4. Large, Targeted Insertions

        10.2.5. ES Cell Modification (Homologous Recombination)

        10.2.6. Others

    10.3. Market Value Forecast By End-user, 2017–2031

        10.3.1. Pharmaceutical Companies

        10.3.2. Biotechnology Companies

        10.3.3. Academic and Research Facilities

        10.3.4. Contract Research and Manufacturing Organizations

    10.4. Market Value Forecast By End-user by Technology, 2017–2031

        10.4.1. Pharmaceutical Companies

            10.4.1.1. CRISPR Knockout

            10.4.1.2. CRISPR Knockin

            10.4.1.3. Random Insertions

            10.4.1.4. Large, Targeted Insertions

            10.4.1.5. ES Cell Modification (Homologous Recombination)

            10.4.1.6. Others

        10.4.2. Biotechnology Companies

            10.4.2.1. CRISPR Knockout

            10.4.2.2. CRISPR Knockin

            10.4.2.3. Random Insertions

            10.4.2.4. Large, Targeted Insertions

            10.4.2.5. ES Cell Modification (Homologous Recombination)

            10.4.2.6. Others

        10.4.3. Academic and Research Facilities

            10.4.3.1. CRISPR Knockout

            10.4.3.2. CRISPR Knockin

            10.4.3.3. Random Insertions

            10.4.3.4. Large, Targeted Insertions

            10.4.3.5. ES Cell Modification (Homologous Recombination)

            10.4.3.6. Others

        10.4.4. Contract Research and Manufacturing Organizations

            10.4.4.1. CRISPR Knockout

            10.4.4.2. CRISPR Knockin

            10.4.4.3. Random Insertions

            10.4.4.4. Large, Targeted Insertions

            10.4.4.5. ES Cell Modification (Homologous Recombination)

            10.4.4.6. Others

    10.5. Market Value Forecast By Country/Sub-Region, 2017–2031

        10.5.1. Germany

        10.5.2. U.K.

        10.5.3. France

        10.5.4. Spain

        10.5.5. Italy

        10.5.6. Rest of Europe

    10.6. Market Attractiveness Analysis

        10.6.1. By Technology

        10.6.2. By End-user

        10.6.3. By End-user by Technology

        10.6.4. By Country/Sub-Region

11. Asia Pacific Mice Model Technologies Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast By Technology, 2017–2031

        11.2.1. CRISPR Knockout

        11.2.2. CRISPR Knockin

        11.2.3. Random Insertions

        11.2.4. Large, Targeted Insertions

        11.2.5. ES Cell Modification (Homologous Recombination)

        11.2.6. Others

    11.3. Market Value Forecast By End-user, 2017–2031

        11.3.1. Pharmaceutical Companies

        11.3.2. Biotechnology Companies

        11.3.3. Academic and Research Facilities

        11.3.4. Contract Research and Manufacturing Organizations

    11.4. Market Value Forecast By End-user by Technology, 2017–2031

        11.4.1. Pharmaceutical Companies

            11.4.1.1. CRISPR Knockout

            11.4.1.2. CRISPR Knockin

            11.4.1.3. Random Insertions

            11.4.1.4. Large, Targeted Insertions

            11.4.1.5. ES Cell Modification (Homologous Recombination)

            11.4.1.6. Others

        11.4.2. Biotechnology Companies

            11.4.2.1. CRISPR Knockout

            11.4.2.2. CRISPR Knockin

            11.4.2.3. Random Insertions

            11.4.2.4. Large, Targeted Insertions

            11.4.2.5. ES Cell Modification (Homologous Recombination)

            11.4.2.6. Others

        11.4.3. Academic and Research Facilities

            11.4.3.1. CRISPR Knockout

            11.4.3.2. CRISPR Knockin

            11.4.3.3. Random Insertions

            11.4.3.4. Large, Targeted Insertions

            11.4.3.5. ES Cell Modification (Homologous Recombination)

            11.4.3.6. Others

        11.4.4. Contract Research and Manufacturing Organizations

            11.4.4.1. CRISPR Knockout

            11.4.4.2. CRISPR Knockin

            11.4.4.3. Random Insertions

            11.4.4.4. Large, Targeted Insertions

            11.4.4.5. ES Cell Modification (Homologous Recombination)

            11.4.4.6. Others

    11.5. Market Value Forecast By Country/Sub-Region, 2017–2031

        11.5.1. China

        11.5.2. Japan

        11.5.3. India

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Market Attractiveness Analysis

        11.6.1. By Technology

        11.6.2. By End-user

        11.6.3. By End-user by Technology

        11.6.4. By Country/Sub-Region

12. Latin America Mice Model Technologies Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Technology, 2017–2031

        12.2.1. CRISPR Knockout

        12.2.2. CRISPR Knockin

        12.2.3. Random Insertions

        12.2.4. Large, Targeted Insertions

        12.2.5. ES Cell Modification (Homologous Recombination)

        12.2.6. Others

    12.3. Market Value Forecast By End-user, 2017–2031

        12.3.1. Pharmaceutical Companies

        12.3.2. Biotechnology Companies

        12.3.3. Academic and Research Facilities

        12.3.4. Contract Research and Manufacturing Organizations

    12.4. Market Value Forecast By End-user by Technology, 2017–2031

        12.4.1. Pharmaceutical Companies

            12.4.1.1. CRISPR Knockout

            12.4.1.2. CRISPR Knockin

            12.4.1.3. Random Insertions

            12.4.1.4. Large, Targeted Insertions

            12.4.1.5. ES Cell Modification (Homologous Recombination)

            12.4.1.6. Others

        12.4.2. Biotechnology Companies

            12.4.2.1. CRISPR Knockout

            12.4.2.2. CRISPR Knockin

            12.4.2.3. Random Insertions

            12.4.2.4. Large, Targeted Insertions

            12.4.2.5. ES Cell Modification (Homologous Recombination)

            12.4.2.6. Others

        12.4.3. Academic and Research Facilities

            12.4.3.1. CRISPR Knockout

            12.4.3.2. CRISPR Knockin

            12.4.3.3. Random Insertions

            12.4.3.4. Large, Targeted Insertions

            12.4.3.5. ES Cell Modification (Homologous Recombination)

            12.4.3.6. Others

        12.4.4. Contract Research and Manufacturing Organizations

            12.4.4.1. CRISPR Knockout

            12.4.4.2. CRISPR Knockin

            12.4.4.3. Random Insertions

            12.4.4.4. Large, Targeted Insertions

            12.4.4.5. ES Cell Modification (Homologous Recombination)

            12.4.4.6. Others

    12.5. Market Value Forecast By Country/Sub-Region, 2017–2031

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Market Attractiveness Analysis

        12.6.1. By Technology

        12.6.2. By End-user

        12.6.3. By End-user by Technology

        12.6.4. By Country/Sub-Region

13. Middle East & Africa Mice Model Technologies Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Technology, 2017–2031

        13.2.1. CRISPR Knockout

        13.2.2. CRISPR Knockin

        13.2.3. Random Insertions

        13.2.4. Large, Targeted Insertions

        13.2.5. ES Cell Modification (Homologous Recombination)

        13.2.6. Others

    13.3. Market Value Forecast By End-user, 2017–2031

        13.3.1. Pharmaceutical Companies

        13.3.2. Biotechnology Companies

        13.3.3. Academic and Research Facilities

        13.3.4. Contract Research and Manufacturing Organizations

    13.4. Market Value Forecast By End-user by Technology, 2017–2031

        13.4.1. Pharmaceutical Companies

            13.4.1.1. CRISPR Knockout

            13.4.1.2. CRISPR Knockin

            13.4.1.3. Random Insertions

            13.4.1.4. Large, Targeted Insertions

            13.4.1.5. ES Cell Modification (Homologous Recombination)

            13.4.1.6. Others

        13.4.2. Biotechnology Companies

            13.4.2.1. CRISPR Knockout

            13.4.2.2. CRISPR Knockin

            13.4.2.3. Random Insertions

            13.4.2.4. Large, Targeted Insertions

            13.4.2.5. ES Cell Modification (Homologous Recombination)

            13.4.2.6. Others

        13.4.3. Academic and Research Facilities

            13.4.3.1. CRISPR Knockout

            13.4.3.2. CRISPR Knockin

            13.4.3.3. Random Insertions

            13.4.3.4. Large, Targeted Insertions

            13.4.3.5. ES Cell Modification (Homologous Recombination)

            13.4.3.6. Others

        13.4.4. Contract Research and Manufacturing Organizations

            13.4.4.1. CRISPR Knockout

            13.4.4.2. CRISPR Knockin

            13.4.4.3. Random Insertions

            13.4.4.4. Large, Targeted Insertions

            13.4.4.5. ES Cell Modification (Homologous Recombination)

            13.4.4.6. Others

    13.5. Market Value Forecast By Country/Sub-Region, 2017–2031

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of Middle East & Africa

    13.6. Market Attractiveness Analysis

        13.6.1. By Technology

        13.6.2. By End-user

        13.6.3. By End-user by Technology

        13.6.4. By Country/Sub-Region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis By Company (2021)

        14.2.1. Global

        14.2.2. North America

        14.2.3. Europe

        14.2.4. By Asia-Pacific

        14.2.5. By Latin America

        14.2.6. By Middle East & Africa

    14.3. Company Profiles

        14.3.1. BIOCYTOGEN

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Strategic Overview

        14.3.2. Charles River Laboratories

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Strategic Overview

        14.3.3. Cyagen Biosciences

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Strategic Overview

        14.3.4. Gempharmatech

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. genOway

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Strategic Overview

        14.3.6. ingenious targeting laboratory

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Strategic Overview

        14.3.7. Merck KGaA

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Strategic Overview

        14.3.8. Ozgene Pty Ltd.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. SWOT Analysis

            14.3.8.4. Strategic Overview

        14.3.9. Taconic Biosciences, Inc.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. SWOT Analysis

            14.3.9.4. Strategic Overview

        14.3.10. PolyGene AG

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Product Portfolio

            14.3.10.3. SWOT Analysis

            14.3.10.4. Strategic Overview

        14.3.11. THE JACKSON LABORATORY

            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.11.2. Product Portfolio

            14.3.11.3. SWOT Analysis

            14.3.11.4. Strategic Overview

        14.3.12. Yale School of Medicine

            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.12.2. Product Portfolio

            14.3.12.3. SWOT Analysis

            14.3.12.4. Strategic Overview

        14.3.13. University of North Carolina

            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.13.2. Product Portfolio

            14.3.13.3. SWOT Analysis

            14.3.13.4. Strategic Overview

        14.3.14. University of Nebraska Medical Center

            14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.14.2. Product Portfolio

            14.3.14.3. SWOT Analysis

            14.3.14.4. Strategic Overview

        14.3.15. Monash University

            14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.15.2. Product Portfolio

            14.3.15.3. SWOT Analysis

            14.3.15.4. Strategic Overview

        14.3.16. UMass Chan Medical School

            14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.16.2. Product Portfolio

            14.3.16.3. SWOT Analysis

            14.3.16.4. Strategic Overview

        14.3.17. University of Bonn

            14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.17.2. Product Portfolio

            14.3.17.3. SWOT Analysis

            14.3.17.4. Strategic Overview

        14.3.18. Columbia University

            14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.18.2. Product Portfolio

            14.3.18.3. SWOT Analysis

            14.3.18.4. Strategic Overview

        14.3.19. The University of Arizona

            14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.19.2. Product Portfolio

            14.3.19.3. SWOT Analysis

            14.3.19.4. Strategic Overview

List of Tables

Table 01: Price/Cost Analysis of Mice Models, by Region

Table 02: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 03: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 04: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 05: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 06: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017‒2031

Table 07: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

Table 08: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 09: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 11: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 12: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 13: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 14: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017‒2031

Table 15: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

Table 16: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 17: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 18: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 19: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 20: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 21: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017‒2031

Table 22: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

Table 23: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 24: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 25: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 26: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 27: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 28: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017‒2031

Table 29: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

Table 30: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 31: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 32: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 33: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 34: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 35: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031

Table 36: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

Table 37: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 38: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017‒2031

Table 39: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 40: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031

Table 41: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031

Table 42: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017‒2031

Table 43: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017‒2031

List of Figures

Figure 01: Global Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Mice Model Technologies Market Value Share, by Technology, 2021

Figure 03: Mice Model Technologies Market Value Share, by End-user, 2021

Figure 04: Mice Model Technologies Market Value Share, by Region, 2021

Figure 05: Global Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 06: Global Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022–2031

Figure 07: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockout, 2017‒2031

Figure 08: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockin Mice, 2017‒2031

Figure 09: Global Mice Model Technologies Market Value (US$ Mn), by Random Insertions, 2017‒2031

Figure 10: Global Mice Model Technologies Market Value (US$ Mn), by Large, Targeted Insertions, 2017‒2031

Figure 11: Global Mice Model Technologies Market Value (US$ Mn), by ES Cell Modification (Homologous Recombination), 2017‒2031

Figure 12: Global Mice Model Technologies Market Value (US$ Mn), by Others, 2017‒2031

Figure 13: Global Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 14: Global Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Figure 15: Global Mice Model Technologies Market Value (US$ Mn), by Pharmaceutical Companies, 2017‒2031

Figure 16: Global Mice Model Technologies Market Value (US$ Mn), by Biotechnology Companies, 2017‒2031

Figure 17: Global Mice Model Technologies Market Value (US$ Mn), by Academic and Research Facilities, 2017‒2031

Figure 18: Global Mice Model Technologies Market Value (US$ Mn), by Contract Research and Manufacturing Organizations, 2017‒2031

Figure 19: Global Mice Model Technologies Market Value Share Analysis, by Region, 2021 and 2031

Figure 20: Global Mice Model Technologies Market Attractiveness Analysis, by Region, 2022–2031

Figure 21: North America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 22: North America Mice Model Technologies Market Attractiveness Analysis, by Country, 2022–2031 

Figure 23: North America Mice Model Technologies Market Value Share Analysis, by Country, 2021 and 2031

Figure 24: North America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 25: North America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022–2031

Figure 26: North America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 27: North America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Figure 28: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 29: Europe Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 30: Europe Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 31: Europe Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 32: Europe Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022–2031

Figure 33: Europe Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 34: Europe Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Figure 35: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 36: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 37: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 38: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 39: Asia Pacific Mice Model Technologies Market Attractiveness Index, by Technology, 2022–2031

Figure 40: Asia Pacific Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 41: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Figure 42: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 43: Latin America Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 44: Latin America Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

Figure 45: Latin America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 46: Latin America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022–2031

Figure 47: Latin America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 48: Latin America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Figure 49: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, 2017–2031

Figure 50: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 51: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

Figure 52: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031

Figure 53: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022–2031

Figure 54: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031

Figure 55: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

505

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved